Evommune (EVMN) Chief Business & Legal Officer reports RSU tax share withholding

Rhea-AI Filing Summary

Evommune, Inc. executive Gregory S. Moss, the company’s Chief Business & Legal Officer, reported an insider transaction involving company stock. On 12/09/2025, 13,624 shares of Evommune common stock were withheld at a price of $17.84 per share to cover his tax withholding obligations tied to the settlement of restricted stock units. After this transaction, he directly beneficially owned 60,835 shares of common stock and indirectly held 3,175 additional shares through a family trust in which he serves as trustee.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Moss Gregory S.

Role Chief Business & Legal Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	13,624	$17.84	$243K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 60,835 shares (Direct); Common Stock — 3,175 shares (Indirect, By Trust)

Footnotes (1)

1. Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units. The securities are held by a family trust, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Moss Gregory S.

(Last) (First) (Middle)

C/O EVOMMUNE, INC.

1841 PAGE MILL ROAD, SUITE 100

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Evommune, Inc. [ EVMN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business & Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/09/2025		F		13,624(1)	D	$17.84	60,835	D
Common Stock								3,175	I	By Trust(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

2. The securities are held by a family trust, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.

Remarks:

	/s/ Gregory S. Moss	12/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Evommune (EVMN) report for Gregory S. Moss?

The filing reports that 13,624 shares of Evommune common stock were withheld on 12/09/2025 to satisfy Gregory S. Moss’s tax withholding obligations related to the settlement of restricted stock units.

What role does Gregory S. Moss hold at Evommune (EVMN)?

Gregory S. Moss serves as Chief Business & Legal Officer of Evommune, Inc., and filed this Form 4 as an officer of the company.

At what price were the Evommune (EVMN) shares withheld for taxes?

The 13,624 shares were withheld at a price of $17.84 per share in connection with the settlement of restricted stock units.

How many Evommune (EVMN) shares does Gregory S. Moss own after this transaction?

Following the reported transaction, Gregory S. Moss beneficially owned 60,835 Evommune common shares directly and 3,175 shares indirectly through a family trust.

What is the nature of Gregory S. Moss’s indirect ownership of Evommune (EVMN) shares?

His indirect ownership consists of 3,175 shares held by a family trust, for which he is a trustee; he disclaims beneficial ownership except to the extent of his proportionate pecuniary interest.

Was the Evommune (EVMN) insider transaction part of a tax-related event?

Yes. The filing explains that the 13,624 shares were withheld to satisfy tax withholding obligations arising from the settlement of restricted stock units.